PSA-based vaccines for the treatment of prostate cancer

Expert Review of Vaccines

Volumn 5, Issue 2, 2006, Pages 199-209

  Madan, Ravi A ^a   Gulley, James L ^a   Arlen, Philip M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Agonist epitopes; Costimulatory molecule; Dendritic cell; Enzyme linked immunosorbent spot assay; Peptide; Pox vector; Prostate specific antigen; Recombinant vaccine; Vaccine

Indexed keywords

BCG VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DNA VACCINE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; HUMAN; INJECTION SITE REACTION; NONHUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; BIOSYNTHESIS; IMMUNOLOGY; MALE; METABOLISM; PROSTATE TUMOR;

CANCER VACCINES; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33746670624     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.2.199     Document Type: Review

References (65)

1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238-244 (2005).
2. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145(5), 907-923 (1991).
3. Wang MC, Kuriyama M, Papsidero LD, Loor RM, Valenzuela LA, Murphy GP. Prostate antigen of human cancer patients. In: Methods in Cancer Research Vol. XIX, Busch H, Yeoman LC (Eds), Academic Press, NY, USA, 179 (1982).
4. Chakraborty NG, Steven RL, Mehrotra et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol. Immunother. 52(8), 497-505 (2003)
5. Elkord E, Rowbottom AW, Kynaston H et al. Correlation between CD8(+) T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin. Immunol. (Epub) (2006).
6. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin. Oncol. 30(5), 649-658 (2003).
7. Correale P, Walmsley K, Nieroda C et al. In vitro generation of human cytotoxic T cells specific for peptides derived from human prostate-specific antigen. J. Natl Cancer Inst. 89(4), 293-300 (1997).
8. Correale P, Walmsley K, Zaremba S, Zhu MZ, Schlom J, Tsang KY. Generation of human cytolytic lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J. Immunol. 161(6), 3186-3194 (1998).
9. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 30(2), 73-78 (1997).
10. Terasawa H, Tsang KY, Gulley J, Arlen P, Schlom J. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin. Cancer Res. 8(1), 41-53 (2002).
11. Perambakam S, Hallmeyer S, Reddy S. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother. 1-10 (Epub) (2005).
12. Harada M, Matsueda S, Yao A, Noguchi M, Itoh K. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patients J. Immunother. 28, 368-375 (2005). • Demonstrated the ability of a patient to generate a humoral immune response to a different prostrate-specific antigen (PSA) peptide (PSA 248-257).
13. Salgaller ML. Prostate cancer immunotherapy at the dawn of the new millennium. Expert Opin. Investig. Drugs 9(6), 1217-1229 (2000).
14. Harris DT, Matyas GR, Gomella LG et al. Immunologic approaches to the treatment of prostate cancer. Semin. Oncol. 26(4), 439-447 (1999).
15. Meidenbauer N, Harris DT, Spitler LE, Whiteside TL. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43, 88-100 (2000).
16. Stevenson FK, Ottensmeier CH, Johnson P et al. DNA vaccines to attack cancer. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14646-14652 (2004).
17. Kim JJ, Yang JS, Nottingham LK et al. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogen 20, 4497-4506 (2001).
18. Wolchok JD, Gregor PD, Nordquist LT et al. DNA vaccines: an active immunization strategy in prostate cancer. Semin. Oncol. 30, 659-666 (2003).
19. Pavlenko M, Ross AK, Lundqvist A et al. A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigens in patients with hormone-refractory prostate cancer. Br. J. Cancer 91, 688-694 (2004).
20. Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in a Phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J. Immunother. 28, 389-395 (2005).
21. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46(2), 82-87 (1998).
22. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186(7), 1177-1182 (1997).
23. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184(2), 465-472 (1996).
24. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa El. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16(4), 364-369 (1998).
25. Hung CF, Cheng WF, He L et al. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res. 63(10), 2393-2398 (2003).
26. + T-cell responses. Blood 105(9), 3596-3604 (2005).
27. Heiser A, Dahm P, Yancey DR et al. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164(10), 5508-5514 (2000).
28. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109(3), 409-417 (2002). •• This Phase I clinical study evaluated the safety of dose escalations of PSA-RNA-transfected dendritic cells (DCs) in patients with metastatic prostate cancer. Administration of PSA-RNA-loaded DCs stimulated the induction of PSA-specific T-cell responses without toxicity in all study patients among all dose levels tested. A decrease in the log serum PSA slope in six out of seven evaluable patients was observed.
29. Barrou B, Benoit G, Ouldkaci M et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. 53(5), 453-460 (2004).
30. Juillard V, Villefroy P, Godfrin D et al. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Immunol. 259(12), 3467-3473 (1995).
31. Chen PW, Wang M, Bronte V et al. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J. Immunol. 156(1), 224-231 (1996).
32. Xiang ZQ, Yang Y, Wilson JM et al. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219(1), 220-227 (1996).
33. Rosenberg SA, Zhai Y, Yang JC et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl Cancer Inst. 90(24), 1894-1900 (1998).
34. Kantor J, Abrams S, Irvine K, Snoy P, Kaufman H, Schlom J. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann. NY Acad. Sci. 690, 370-373 (1993).
35. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59(3), 676-683 (1999).
36. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA, Panicali D. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc. Natl Acad. Sci. USA 84(19), 6854-6858 (1987).
37. Sanda M, Smith D, Charles LG et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53(2), 260-266 (1999).
38. Eder JP, Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6(5), 1632-1638 (2000).
39. Gulley J, Chen AP, Dahut W et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen independent prostate cancer. Prostate 53(2), 109-117 (2002).
40. Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 15(6-7), 759-768 (1997).
41. Grosenbach DW Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and anti-tumor effects. Cancer Res. 61(11), 4497-4505 (2001).
42. Kaufman HL, Wang W, Manola J et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(11), 2122-2132 (2004).
43. Kaufman HL, Wang W, Manola J et al. 2005 ASCO Annual Meeting Proceedings. J. Clin. Oncol. 23(No 16S, June 1 Supplement), Abstract 4501 (2005). •• Patients were randomized to receive recombinant poxvirus vectors with the gene for PSA. There was a substantial difference in PSA progression-free survival favoring the use of vaccinia priming and avipox vector boosting.
44. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71(7), 1065-1068 (1992).
45. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71(7), 1093-1102 (1992).
46. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, and Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol. 143(8), 2714-2722 (1989).
47. Freeman GJ, Gray GS, Gimmi CD et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174(3), 625-631 (1991).
48. Springer TA. Adhesion receptors of the immune system. Nature 346(6283), 425-434 (1990).
49. Hellstrom KE, Hellstrom I, Linsley P, Chen L. On the role of costimulation in tumor immunity. Ann. NY Acad. Sci. 690, 225-230 (1993).
50. Hellstrom I, Hellstrom KE. Tumor immunology: an overview. Ann. NY Acad. Sci. 690, 24-31 (1993).
51. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J. Exp. Med. 167(6), 1811-1824 (1988).
52. + T lymphocytes. J. Immunol. 148(7), 1985-1992 (1992).
53. Gulley JL, Arlen PM, Bastian A et al. Ability to employ a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11(9), 3353-3362 (2005).
54. Arlen PM, Gulley JL, Todd N et al. A randomized Phase II Trial of either vaccine therapy (recombinant pox viruses expressing PSA and the B7.1 costimulatory molecule) versus hormone therapy (Nilutamide) in patients with hormone refractory prostate cancer and no radiographic evidence of disease. J. Urol. 174(2), 539-546 (2005). •• Hormone refractory prostate cancer patients with no measurable disease on scans were randomized to receive a pox vector PSA vaccine versus the androgen receptor antagonist nilutamide. The results suggest that the addition of hormone therapy following initial vaccine therapy may lead to an improved clinical benefit compared with hormone therapy alone.
55. Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen independent prostate cancer. Clin. Cancer Res. 12(4), 1260-1269 (2006).
56. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MGO, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999).
57. Arlen PM, Gulley J, Dahut W et al. A Phase I study of sequential vaccinations with recombinant Fowlpox-PSA (L155)-TRICOM (rF) alone, or in combination with recombinant vaccinia-PSA (L155)-TRICOM (rV), and the role of GM-CSF, in patients (Pts) with prostate cancer. Abstr. Am. Soc. Clin. Oncol. 24, Abstract 2522 (2004).
58. Gulley J, Todd N, Dahut W, Schlom J, Arlen P. A Phase II study of a PSA-TRICOM vaccine, and the role of GM-CSF, in patients (pts) with metastatic androgen insensitive prostate cancer (AIPC). Abstr. Am. Soc. Clin. Oncol. Prostate Ca. Symposium 1, Abstract 256 (2005). • Vaccinia and fowlpox vectors containing the gene for human PSA with a single amino acid substitution (designated PSA L155) along with genes encoding triad of co-stimulatory molecules (TRICOM) are safe and elicit PSA declines in hormone refractory metastatic prostate cancer patients.
59. Foss FM. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941, 166-176 (2001).
60. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105(7), 2862-2868 (2005).
61. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999).
62. Kudo-Saito C, Schlom J Hodge JW. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors. Clin. Cancer Res. 11(12), 4533-4544 (2005).
63. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005). • DAB(389)IL-2 (Ontak®)-mediated regulatory T cells depletion can result in enhanced stimulation of proliferative and cytotoxic T-cell responses in vitro, as demonstrated in patients with metastatic renal cell carcinoma.
64. Machiels JP, Reilly RT, Emens LA et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61(9), 3689-3697 (2001).
65. Website 101 Ries LAG, Eisner MP, Kosary CL et al. (Eds). SEER Cancer Statistics Review, 1975-2001, National Cancer Institute. Bethesda, MD, USA http://seer.cancer.gov/csr/1975_2001/2005